Alliqua, Inc. (OTCBB: HPLF) (FWB: HL1) (?Alliqua?), an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, announced today the appointment of industry veteran Dr. Ronald S. Harland, former Principal Scientist of drug delivery at Bristol-Myers Squibb, as a strategic consultant to the company.

Dr. Ronald S. Harland has worked in the field of pharmaceutical product development, as well as the study of advanced drug delivery systems and applications for over 20 years. With extensive experience in creating and commercializing new specialty products in the pharmaceutical industry, he has been instrumental in the commercialization of more than 50 products. Dr. Harland has founded and grown two international drug delivery service companies and his extensive skill set has been bolstered by the fact that he has spent much of his career evaluating and assessing drug delivery systems for companies such as Bristol-Myers Squibb as well as partnering in development programs with companies such as Merck and Novartis.

?Dr. Harland is a strong addition to our team,? said Richard Rosenblum, President and Director of Alliqua. ?His influence in the pharmaceutical and healthcare sectors offers a tremendous resource to our organization as we focus on various transdermal products in development at our Alliqua BioMedical subsidiary. The timing is perfect as we begin to establish a team of well respected authorities in the industry.?

Dr. Harland is currently the Founder and Chief Operating Officer at PharmSolv, LLC, which employs proprietary drug delivery systems to administer poorly soluble or poorly absorbed drugs to the body. Dr. Harland graduated from Purdue University with his Doctorate Degree in Chemical Engineering.

Dr. Harland commented, ?I'm excited to become a member of the Alliqua team and look forward to helping Alliqua capitalize on its emerging technologies in the fields of transdermal drug delivery and advanced wound care.?

Alliqua's strategic initiatives have evolved around the concept of utilizing its proprietary and patented technologies to address drug delivery and advanced wound care needs through the use of its AquaMed subsidiary's proprietary hydrogel platform. Hydrogels are gel-like or colloidal substances made of water and solids that are highly absorbent, and are well suited for wound care and transdermal purposes. Alliqua's dressings create a moist environment that facilitates healing, naturally produces pain relief at the wound site, and inherently stays in place without bonding to the wound, skin or hair.

About Alliqua Inc.

Alliqua, Inc. (?Alliqua?), formerly HepaLife Technologies, Inc., (OTCBB: HPLF) (FWB: HL1), is an advanced biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. Through its wholly-owned subsidiary, Alliqua BioMedical, Inc., Alliqua intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by Alliqua's AquaMed Technologies, Inc. (?AquaMed?) subsidiary.

AquaMed manufactures custom hydrogels used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics. These products use proprietary manufacturing technologies which enable AquaMed to produce what is known in the healthcare industry as high water content, electron beam cross-linked aqueous polymer sheet hydrogels. AquaMed believes that it is one of two known manufacturers in the world for these gels. Alliqua's third subsidiary, HepaLife Biosystems, Inc. focuses on the development of a cell-based bioartificial liver system, known as HepaMate?.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.alliqua.com and www.aquamedinc.com.

To receive future press releases via email, please visit: http://alliqua.com/index.php?page=investor-alerts

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like ?may,? ?will,? ?should,? ?could,? ?expect,? ?anticipate,? ?estimate,? ?believe,? ?intend,? or ?project? or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Current Report on Form 8-K filed with the SEC on May 17, 2010 and our most recent Form 10-Q and Form 10-K filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.

Alliqua, Inc.
Steven Berger
646-218-1450